Pharmos(PARS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Pharmos(PARS)

PARS 2.700

+13.6%

Jan 21 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Ariella who wrote (1075)	7/22/1998 9:28:00 AM
From: NeuroInvestment	Read Replies (1) of 1491

1) A clarification regarding the dosage reduction: it was a tactical decision based on the serum levels obtained from the first two doses, which diverged from expectations ( and actually were lower than anticipated). Based on the effects Pharmos thinks (based on results that they state remain blinded) are being obtained from HU211 on the first two cohorts, they decided that 300 would be too large a leap, and would risk hitting a downward slope of diminishing returns. Second, while the Israeli authorities had authorized up to 300mg, some IRBs at individual sites had only authorized up to 200mg, and time would have been consumed by revising those limits. The most important element is that PARS definitively states that the reduction was not due to any adverse effects emerging from the first two cohorts. 2) I would add what may by this point be a superfluous note of support and appreciation for the numerous postings made by Ariella on this thread, which are consistently thoughtful and well-informed,devoid of the blind boosterism that mars so many threads and messages. NeuroInvestment (www.neuroinv.com)

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next